Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9578 posts found.

opdivo_1

Shock for BMS as Opdivo misses goal in late-stage lung cancer trial

August 5, 2016 Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Checkmate, lung cancer, opdivo

Bristol-Myers Squibb has announced that its much heralded cancer therapy, Opdivo (nivolumab), failed to meet its primary endpoint of progression-free …
News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

August 5, 2016 Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten

It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …
News

Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk

August 5, 2016 Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure

Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …
News

Majority of US patients’ groups supporting pharma against Medicare reforms received industry funding, claims report

August 5, 2016 Medical Communications, Research and Development medicare reform, patients' groups, public citizen

An overwhelming majority of US patients’ groups who supported the pharmaceutical industry in opposing Medicare part B pricing reforms receive …
News
regeneron

Eylea sales jump helps boost Regeneron in Q2 results

August 5, 2016 Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results

Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …
News
novartis_iobmr

NICE recommends Cosentyx in ankylosing spondylitis

August 4, 2016 Research and Development, Sales and Marketing Cosentyx, NICE, Novartis, ankylosing spondylitis

Novartis has announced that the National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) to treat adults …
News
20160803-zika-dna-vaccine

NIH launches test of investigational human Zika vaccine

August 4, 2016 Research and Development Vaccine, Zika virus

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun the clinical …
News
fda2outsideweb

FDA determines Xiamen Origin Biotech wilfully lied to inspectors and customers

August 4, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Xiamen Origin Biotech

The US Food and Drug Administration (FDA) carried out an inspection of Chinese drug manufacturer  Xiamen Origin Biotech, finding the …
News
adaptimmune_lab_scientists_growing_research_cells_jpg-web

Bad news for Adaptimmune as partial clinical hold placed on T-cell oncology trial

August 4, 2016 Research and Development Adaptimmune, T cell, oncology, t-cell

Adaptimmune Therapeutics has received notice from the US Food and Drug Administration (FDA) that a partial clinical hold has been …
News
roche_south

Roche cuts ties with Inovio in hepatitis B development

August 3, 2016 Research and Development Inovio, Roche, hepatitis B

Inovio Pharmaceuticals has announced that it will independently continue development of hepatitis B immunotherapy, INO-1800, after Swiss drugmaker Roche issued …
News
biogen_austria_238

Takeover rumours send Biogen’s stock soaring

August 3, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Biogen, MSD, rumours, takeover

Rumours have begun to circulate that companies including MSD and Allergan are plotting a takeover bid for Biogen, after a …
News
celgene_1_02

Celgene’s Otezla approved for NHS use

August 3, 2016 Research and Development, Sales and Marketing Celgene, NHS, NICE, apremilast

NICE has published draft guidance recommending the use of Celgene’s Otezla (apremilast) for use on the NHS for treatment of …
News
teva_copy

Teva completes $40 billion acquisition of Actavis Generics

August 3, 2016 Research and Development, Sales and Marketing Actavis, Allergan, Teva, acqusition, generics

Teva has announced that it has completed its acquisition of Actavis Generics, a subsidiary of Allergan, in a transaction valued …
News
merck_incweb

MSD scores EU approval for Keytruda in lung cancer

August 3, 2016 Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer

MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …
News
novartis_building

Breakthrough therapy designation for Novartis in advanced breast cancer treatment

August 3, 2016 Research and Development, Sales and Marketing Breakthrough Therapy Designation, FDA, LEE011, Novartis, ribociclib

Novartis has announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation to LEE011 (ribociclib) …
News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026